To gain competitive advantage from gen AI, enterprises need to be able to add their own expertise to off-the-shelf systems. Yet standard enterprise data stores aren't a good fit to train large ...

The A2 round was led by Tenacity Ventures, with additional support from Vertex Ventures, Peak XV Partners ... where takeoffs (measuring site areas) from PDFs are a standard procedure owing to ...

“Commercial negotiations between NHS England and Vertex remain on-track and ... Identification Rule tool – This is a software tool which enables the identification of specialised services activity ...

The software and services sector dominated the list with 87 entrants ... The list features 12 women, leading with Reshma Kewalramani of Vertex Pharmaceuticals, followed by Jayshree Ullal of Arista ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...

With its latest update, Regula Document Reader SDK, a comprehensive software solution for identity document verification, ensures 100% support for the new ISO/IEC 39794-5 standard regulating the ...

The ES90 electric vehicle, which is being unveiled on 5 March, will be the first Volvo car equipped with dual Nvidia Drive ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

The Parnassus Growth Equity Fund returned 4.85% (net) for Q4 2024, underperforming the Russell 1000 Growth Index’s 7.07%.

Here's why they think Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years ...